Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

Blood. 2021 Mar 25;137(12):1694-1697. doi: 10.1182/blood.2020007150.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use*
  • Clofarabine / therapeutic use*
  • Humans
  • Leukemia, Myeloid, Acute / diagnosis*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / pathology
  • Neoplasm Recurrence, Local
  • Neoplasm, Residual / diagnosis*
  • Neoplasm, Residual / pathology
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / pathology
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Clofarabine